Prognostic value of pS2 protein and receptors for epidermal growth factor (EGF-R), Insulin-like growth factor-1 (IGF-1-R) and somatostatin (SS-R) in patients with breast and ovarian cancer
The prognostic value of EGF-R, IGF-1-R and SS-R, and of cytosolic estrogen-regulated pS2 protein, was studied in patients (pts) with primary breast and advanced ovarian cancer. Ovarian cancer tissues were negative for pS2 (by immunoradiometric assay) IGF-1-R and EGF-R contents (by ligand binding ass...
Gespeichert in:
| Veröffentlicht in: | Journal of steroid biochemistry and molecular biology 1990-12, Vol.37 (6), p.815-821 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 821 |
|---|---|
| container_issue | 6 |
| container_start_page | 815 |
| container_title | Journal of steroid biochemistry and molecular biology |
| container_volume | 37 |
| creator | Foekens, J.A. van Putten, W.L.J. Portengen, H. Rodenburg, C.J. Reubi, J.-C. Berns, P.M.J.J. Henzen-Logmans, S.C. van der Burg, M.E.L. Alexieva-Figusch, J. Klijn, J.G.M. |
| description | The prognostic value of EGF-R, IGF-1-R and SS-R, and of cytosolic estrogen-regulated pS2 protein, was studied in patients (pts) with primary breast and advanced ovarian cancer. Ovarian cancer tissues were negative for pS2 (by immunoradiometric assay) IGF-1-R and EGF-R contents (by ligand binding assay, LBA) were of no or moderate prognostic value for breast cancer pts (
n = 214). For advanced ovarian cancer pts, EGF-R content determined by LBA (
n = 55) showed no prognostic value, whereas EGF-R status (
n = 55) determined by immunohistochemistry (MoAb 2E9) signiificantly correlated with progression of disease (
P < 0.05). In breast cancer pts, both SS-R and pS2 showed no association with tumor size, nodal status and grade. For pS2 the best cut-off level with respect to relapse-free (RFS) and overall survival (OS) was found to be 11 ng/mg protein. Both SS-R (1 g% SS-R+,
n = 135;
P < 0.04) and pS2 (27% pS2+,
n = 197;
P < 0.001), which were mainly positive in ER+ tumors, were of prognostic value, especially within the subgroups with ER+/PgR+ tumors. Also within N+ and No pts the 5-yr RFS and OS showed a difference between pS2+ and pS2- (33 and 54% for N+, and 31 and 13% difference for No pts). In summary, SS-R and pS2 are valuable pronosticators in breast cancer pts, and prognostic significance of EGF-R in ovarian cancer pts needs further study. |
| doi_str_mv | 10.1016/0960-0760(90)90425-K |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_80253551</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>096007609090425K</els_id><sourcerecordid>80253551</sourcerecordid><originalsourceid>FETCH-LOGICAL-c333t-4c14325862625ceb2693cb123d64fa3f024427bc9f9ef7234aba5e87110a4f633</originalsourceid><addsrcrecordid>eNqFkV1rFDEUhgdR6lr9Bwq5UbbgaD5mksmNIKWtSwuKq9chkzmp0ZnJNMls8b_548x0l4o3CoF8nOe8J7xvUTwn-A3BhL_FkuMSC47XEp9IXNG6vHxQrEgjZEkoxQ-L1T3yuHgS43eMMWNEHBVHlIiG8WpV_PoU_PXoY3IG7XQ_A_IWTVuKpuATuBHpsUMBDEzJh4isDwgm10EYdI-ug79N35DVJhfR-uzivPx88hptxjj3bix79wP-ZkqC1ptMkczdKUc_6JSn65RHrbfb5T2fpnyHMUV063JvG0DHdMf7nQ5Oj8jo0UB4Wjyyuo_w7LAfF1_Pz76cfiivPl5sTt9flYYxlsrKkIrRuuGU09pAS7lkpiWUdbyymllMq4qK1kgrwQrKKt3qGhpBCNaV5YwdF6_2utmUmxliUoOLBvpej-DnqBpMa1bX5L8g4RxzQUUGqz1ogo8xgFVTcIMOPxXBaklXLdGpJToll5XTVZe57cVBf24H6O6bDnHm-stDXUejexuyTS7-0ZaCy1rWmXu35yC7tnMQVDTZcAOdy1kn1Xn374_8Brw7wE8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>16606727</pqid></control><display><type>article</type><title>Prognostic value of pS2 protein and receptors for epidermal growth factor (EGF-R), Insulin-like growth factor-1 (IGF-1-R) and somatostatin (SS-R) in patients with breast and ovarian cancer</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Foekens, J.A. ; van Putten, W.L.J. ; Portengen, H. ; Rodenburg, C.J. ; Reubi, J.-C. ; Berns, P.M.J.J. ; Henzen-Logmans, S.C. ; van der Burg, M.E.L. ; Alexieva-Figusch, J. ; Klijn, J.G.M.</creator><creatorcontrib>Foekens, J.A. ; van Putten, W.L.J. ; Portengen, H. ; Rodenburg, C.J. ; Reubi, J.-C. ; Berns, P.M.J.J. ; Henzen-Logmans, S.C. ; van der Burg, M.E.L. ; Alexieva-Figusch, J. ; Klijn, J.G.M.</creatorcontrib><description>The prognostic value of EGF-R, IGF-1-R and SS-R, and of cytosolic estrogen-regulated pS2 protein, was studied in patients (pts) with primary breast and advanced ovarian cancer. Ovarian cancer tissues were negative for pS2 (by immunoradiometric assay) IGF-1-R and EGF-R contents (by ligand binding assay, LBA) were of no or moderate prognostic value for breast cancer pts (
n = 214). For advanced ovarian cancer pts, EGF-R content determined by LBA (
n = 55) showed no prognostic value, whereas EGF-R status (
n = 55) determined by immunohistochemistry (MoAb 2E9) signiificantly correlated with progression of disease (
P < 0.05). In breast cancer pts, both SS-R and pS2 showed no association with tumor size, nodal status and grade. For pS2 the best cut-off level with respect to relapse-free (RFS) and overall survival (OS) was found to be 11 ng/mg protein. Both SS-R (1 g% SS-R+,
n = 135;
P < 0.04) and pS2 (27% pS2+,
n = 197;
P < 0.001), which were mainly positive in ER+ tumors, were of prognostic value, especially within the subgroups with ER+/PgR+ tumors. Also within N+ and No pts the 5-yr RFS and OS showed a difference between pS2+ and pS2- (33 and 54% for N+, and 31 and 13% difference for No pts). In summary, SS-R and pS2 are valuable pronosticators in breast cancer pts, and prognostic significance of EGF-R in ovarian cancer pts needs further study.</description><identifier>ISSN: 0960-0760</identifier><identifier>EISSN: 1879-1220</identifier><identifier>DOI: 10.1016/0960-0760(90)90425-K</identifier><identifier>PMID: 2178364</identifier><language>eng</language><publisher>Oxford: Elsevier Ltd</publisher><subject>Biological and medical sciences ; Biomarkers, Tumor ; breast ; Breast Neoplasms - diagnosis ; Breast Neoplasms - metabolism ; carcinoma ; epidermal growth factor ; ErbB Receptors - metabolism ; Female ; Gynecology. Andrology. Obstetrics ; Humans ; insulin-like growth factor I ; Insulin-Like Growth Factor I - metabolism ; Mammary gland diseases ; Medical sciences ; Neoplasm Proteins - metabolism ; Ovarian Neoplasms - diagnosis ; Ovarian Neoplasms - metabolism ; ovaries ; Prognosis ; Proteins ; pS2 protein ; receptors ; Receptors, Cell Surface - metabolism ; Receptors, Somatomedin ; somatostatin ; Trefoil Factor-1 ; Tumor Suppressor Proteins ; Tumors</subject><ispartof>Journal of steroid biochemistry and molecular biology, 1990-12, Vol.37 (6), p.815-821</ispartof><rights>1990</rights><rights>1991 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c333t-4c14325862625ceb2693cb123d64fa3f024427bc9f9ef7234aba5e87110a4f633</citedby><cites>FETCH-LOGICAL-c333t-4c14325862625ceb2693cb123d64fa3f024427bc9f9ef7234aba5e87110a4f633</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/096007609090425K$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>309,310,314,776,780,785,786,3537,23909,23910,25118,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=19769595$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/2178364$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Foekens, J.A.</creatorcontrib><creatorcontrib>van Putten, W.L.J.</creatorcontrib><creatorcontrib>Portengen, H.</creatorcontrib><creatorcontrib>Rodenburg, C.J.</creatorcontrib><creatorcontrib>Reubi, J.-C.</creatorcontrib><creatorcontrib>Berns, P.M.J.J.</creatorcontrib><creatorcontrib>Henzen-Logmans, S.C.</creatorcontrib><creatorcontrib>van der Burg, M.E.L.</creatorcontrib><creatorcontrib>Alexieva-Figusch, J.</creatorcontrib><creatorcontrib>Klijn, J.G.M.</creatorcontrib><title>Prognostic value of pS2 protein and receptors for epidermal growth factor (EGF-R), Insulin-like growth factor-1 (IGF-1-R) and somatostatin (SS-R) in patients with breast and ovarian cancer</title><title>Journal of steroid biochemistry and molecular biology</title><addtitle>J Steroid Biochem Mol Biol</addtitle><description>The prognostic value of EGF-R, IGF-1-R and SS-R, and of cytosolic estrogen-regulated pS2 protein, was studied in patients (pts) with primary breast and advanced ovarian cancer. Ovarian cancer tissues were negative for pS2 (by immunoradiometric assay) IGF-1-R and EGF-R contents (by ligand binding assay, LBA) were of no or moderate prognostic value for breast cancer pts (
n = 214). For advanced ovarian cancer pts, EGF-R content determined by LBA (
n = 55) showed no prognostic value, whereas EGF-R status (
n = 55) determined by immunohistochemistry (MoAb 2E9) signiificantly correlated with progression of disease (
P < 0.05). In breast cancer pts, both SS-R and pS2 showed no association with tumor size, nodal status and grade. For pS2 the best cut-off level with respect to relapse-free (RFS) and overall survival (OS) was found to be 11 ng/mg protein. Both SS-R (1 g% SS-R+,
n = 135;
P < 0.04) and pS2 (27% pS2+,
n = 197;
P < 0.001), which were mainly positive in ER+ tumors, were of prognostic value, especially within the subgroups with ER+/PgR+ tumors. Also within N+ and No pts the 5-yr RFS and OS showed a difference between pS2+ and pS2- (33 and 54% for N+, and 31 and 13% difference for No pts). In summary, SS-R and pS2 are valuable pronosticators in breast cancer pts, and prognostic significance of EGF-R in ovarian cancer pts needs further study.</description><subject>Biological and medical sciences</subject><subject>Biomarkers, Tumor</subject><subject>breast</subject><subject>Breast Neoplasms - diagnosis</subject><subject>Breast Neoplasms - metabolism</subject><subject>carcinoma</subject><subject>epidermal growth factor</subject><subject>ErbB Receptors - metabolism</subject><subject>Female</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Humans</subject><subject>insulin-like growth factor I</subject><subject>Insulin-Like Growth Factor I - metabolism</subject><subject>Mammary gland diseases</subject><subject>Medical sciences</subject><subject>Neoplasm Proteins - metabolism</subject><subject>Ovarian Neoplasms - diagnosis</subject><subject>Ovarian Neoplasms - metabolism</subject><subject>ovaries</subject><subject>Prognosis</subject><subject>Proteins</subject><subject>pS2 protein</subject><subject>receptors</subject><subject>Receptors, Cell Surface - metabolism</subject><subject>Receptors, Somatomedin</subject><subject>somatostatin</subject><subject>Trefoil Factor-1</subject><subject>Tumor Suppressor Proteins</subject><subject>Tumors</subject><issn>0960-0760</issn><issn>1879-1220</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1990</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkV1rFDEUhgdR6lr9Bwq5UbbgaD5mksmNIKWtSwuKq9chkzmp0ZnJNMls8b_548x0l4o3CoF8nOe8J7xvUTwn-A3BhL_FkuMSC47XEp9IXNG6vHxQrEgjZEkoxQ-L1T3yuHgS43eMMWNEHBVHlIiG8WpV_PoU_PXoY3IG7XQ_A_IWTVuKpuATuBHpsUMBDEzJh4isDwgm10EYdI-ug79N35DVJhfR-uzivPx88hptxjj3bix79wP-ZkqC1ptMkczdKUc_6JSn65RHrbfb5T2fpnyHMUV063JvG0DHdMf7nQ5Oj8jo0UB4Wjyyuo_w7LAfF1_Pz76cfiivPl5sTt9flYYxlsrKkIrRuuGU09pAS7lkpiWUdbyymllMq4qK1kgrwQrKKt3qGhpBCNaV5YwdF6_2utmUmxliUoOLBvpej-DnqBpMa1bX5L8g4RxzQUUGqz1ogo8xgFVTcIMOPxXBaklXLdGpJToll5XTVZe57cVBf24H6O6bDnHm-stDXUejexuyTS7-0ZaCy1rWmXu35yC7tnMQVDTZcAOdy1kn1Xn374_8Brw7wE8</recordid><startdate>19901220</startdate><enddate>19901220</enddate><creator>Foekens, J.A.</creator><creator>van Putten, W.L.J.</creator><creator>Portengen, H.</creator><creator>Rodenburg, C.J.</creator><creator>Reubi, J.-C.</creator><creator>Berns, P.M.J.J.</creator><creator>Henzen-Logmans, S.C.</creator><creator>van der Burg, M.E.L.</creator><creator>Alexieva-Figusch, J.</creator><creator>Klijn, J.G.M.</creator><general>Elsevier Ltd</general><general>Elsevier Science</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>8FD</scope><scope>FR3</scope><scope>M7Z</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>19901220</creationdate><title>Prognostic value of pS2 protein and receptors for epidermal growth factor (EGF-R), Insulin-like growth factor-1 (IGF-1-R) and somatostatin (SS-R) in patients with breast and ovarian cancer</title><author>Foekens, J.A. ; van Putten, W.L.J. ; Portengen, H. ; Rodenburg, C.J. ; Reubi, J.-C. ; Berns, P.M.J.J. ; Henzen-Logmans, S.C. ; van der Burg, M.E.L. ; Alexieva-Figusch, J. ; Klijn, J.G.M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c333t-4c14325862625ceb2693cb123d64fa3f024427bc9f9ef7234aba5e87110a4f633</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1990</creationdate><topic>Biological and medical sciences</topic><topic>Biomarkers, Tumor</topic><topic>breast</topic><topic>Breast Neoplasms - diagnosis</topic><topic>Breast Neoplasms - metabolism</topic><topic>carcinoma</topic><topic>epidermal growth factor</topic><topic>ErbB Receptors - metabolism</topic><topic>Female</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Humans</topic><topic>insulin-like growth factor I</topic><topic>Insulin-Like Growth Factor I - metabolism</topic><topic>Mammary gland diseases</topic><topic>Medical sciences</topic><topic>Neoplasm Proteins - metabolism</topic><topic>Ovarian Neoplasms - diagnosis</topic><topic>Ovarian Neoplasms - metabolism</topic><topic>ovaries</topic><topic>Prognosis</topic><topic>Proteins</topic><topic>pS2 protein</topic><topic>receptors</topic><topic>Receptors, Cell Surface - metabolism</topic><topic>Receptors, Somatomedin</topic><topic>somatostatin</topic><topic>Trefoil Factor-1</topic><topic>Tumor Suppressor Proteins</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Foekens, J.A.</creatorcontrib><creatorcontrib>van Putten, W.L.J.</creatorcontrib><creatorcontrib>Portengen, H.</creatorcontrib><creatorcontrib>Rodenburg, C.J.</creatorcontrib><creatorcontrib>Reubi, J.-C.</creatorcontrib><creatorcontrib>Berns, P.M.J.J.</creatorcontrib><creatorcontrib>Henzen-Logmans, S.C.</creatorcontrib><creatorcontrib>van der Burg, M.E.L.</creatorcontrib><creatorcontrib>Alexieva-Figusch, J.</creatorcontrib><creatorcontrib>Klijn, J.G.M.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biochemistry Abstracts 1</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of steroid biochemistry and molecular biology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Foekens, J.A.</au><au>van Putten, W.L.J.</au><au>Portengen, H.</au><au>Rodenburg, C.J.</au><au>Reubi, J.-C.</au><au>Berns, P.M.J.J.</au><au>Henzen-Logmans, S.C.</au><au>van der Burg, M.E.L.</au><au>Alexieva-Figusch, J.</au><au>Klijn, J.G.M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prognostic value of pS2 protein and receptors for epidermal growth factor (EGF-R), Insulin-like growth factor-1 (IGF-1-R) and somatostatin (SS-R) in patients with breast and ovarian cancer</atitle><jtitle>Journal of steroid biochemistry and molecular biology</jtitle><addtitle>J Steroid Biochem Mol Biol</addtitle><date>1990-12-20</date><risdate>1990</risdate><volume>37</volume><issue>6</issue><spage>815</spage><epage>821</epage><pages>815-821</pages><issn>0960-0760</issn><eissn>1879-1220</eissn><abstract>The prognostic value of EGF-R, IGF-1-R and SS-R, and of cytosolic estrogen-regulated pS2 protein, was studied in patients (pts) with primary breast and advanced ovarian cancer. Ovarian cancer tissues were negative for pS2 (by immunoradiometric assay) IGF-1-R and EGF-R contents (by ligand binding assay, LBA) were of no or moderate prognostic value for breast cancer pts (
n = 214). For advanced ovarian cancer pts, EGF-R content determined by LBA (
n = 55) showed no prognostic value, whereas EGF-R status (
n = 55) determined by immunohistochemistry (MoAb 2E9) signiificantly correlated with progression of disease (
P < 0.05). In breast cancer pts, both SS-R and pS2 showed no association with tumor size, nodal status and grade. For pS2 the best cut-off level with respect to relapse-free (RFS) and overall survival (OS) was found to be 11 ng/mg protein. Both SS-R (1 g% SS-R+,
n = 135;
P < 0.04) and pS2 (27% pS2+,
n = 197;
P < 0.001), which were mainly positive in ER+ tumors, were of prognostic value, especially within the subgroups with ER+/PgR+ tumors. Also within N+ and No pts the 5-yr RFS and OS showed a difference between pS2+ and pS2- (33 and 54% for N+, and 31 and 13% difference for No pts). In summary, SS-R and pS2 are valuable pronosticators in breast cancer pts, and prognostic significance of EGF-R in ovarian cancer pts needs further study.</abstract><cop>Oxford</cop><pub>Elsevier Ltd</pub><pmid>2178364</pmid><doi>10.1016/0960-0760(90)90425-K</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0960-0760 |
| ispartof | Journal of steroid biochemistry and molecular biology, 1990-12, Vol.37 (6), p.815-821 |
| issn | 0960-0760 1879-1220 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_80253551 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Biological and medical sciences Biomarkers, Tumor breast Breast Neoplasms - diagnosis Breast Neoplasms - metabolism carcinoma epidermal growth factor ErbB Receptors - metabolism Female Gynecology. Andrology. Obstetrics Humans insulin-like growth factor I Insulin-Like Growth Factor I - metabolism Mammary gland diseases Medical sciences Neoplasm Proteins - metabolism Ovarian Neoplasms - diagnosis Ovarian Neoplasms - metabolism ovaries Prognosis Proteins pS2 protein receptors Receptors, Cell Surface - metabolism Receptors, Somatomedin somatostatin Trefoil Factor-1 Tumor Suppressor Proteins Tumors |
| title | Prognostic value of pS2 protein and receptors for epidermal growth factor (EGF-R), Insulin-like growth factor-1 (IGF-1-R) and somatostatin (SS-R) in patients with breast and ovarian cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T23%3A44%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prognostic%20value%20of%20pS2%20protein%20and%20receptors%20for%20epidermal%20growth%20factor%20(EGF-R),%20Insulin-like%20growth%20factor-1%20(IGF-1-R)%20and%20somatostatin%20(SS-R)%20in%20patients%20with%20breast%20and%20ovarian%20cancer&rft.jtitle=Journal%20of%20steroid%20biochemistry%20and%20molecular%20biology&rft.au=Foekens,%20J.A.&rft.date=1990-12-20&rft.volume=37&rft.issue=6&rft.spage=815&rft.epage=821&rft.pages=815-821&rft.issn=0960-0760&rft.eissn=1879-1220&rft_id=info:doi/10.1016/0960-0760(90)90425-K&rft_dat=%3Cproquest_cross%3E80253551%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=16606727&rft_id=info:pmid/2178364&rft_els_id=096007609090425K&rfr_iscdi=true |